Welcome to our dedicated page for Surmodics SEC filings (Ticker: SRDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Surmodics, Inc. (SRDX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other key documents. These filings offer detailed information on Surmodics’ medical device and in vitro diagnostics operations, corporate transactions, and regulatory events.
For Surmodics, recent Form 8-K filings have documented material events such as quarterly financial results, a cyber incident, and the acquisition of the company by an affiliate of GTCR LLC. One Form 8-K describes the discovery of a third-party cyber incident affecting certain information technology systems, the company’s containment and remediation efforts, and the role of its cyber insurance coverage. Other 8-K filings furnish press releases reporting quarterly revenue, segment performance in the Medical Device and In Vitro Diagnostics businesses, and updated fiscal year financial guidance.
A significant Form 8-K filed on November 19, 2025, details the completion of the merger between Surmodics and BCE Merger Sub, Inc., an affiliate of GTCR. This filing explains that Merger Sub merged with and into Surmodics, with Surmodics surviving as a wholly owned subsidiary of BCE Parent, LLC. It describes the cash consideration paid per share of common stock, the treatment of equity awards, repayment and termination of the company’s credit agreement and related interest rate swap, and the resulting change in control. The filing also outlines Surmodics’ notifications to Nasdaq, the request for a Form 25 to delist its common stock, and the intention to file a Form 15 to deregister the stock and suspend Exchange Act reporting obligations.
Additional filings address governance and leadership changes triggered by the merger, including the resignation of prior directors and officers and the appointment of new directors and executive officers in accordance with the merger agreement. These documents provide structured information on the company’s post-transaction corporate structure and governing documents, such as amended and restated articles of incorporation and bylaws.
On Stock Titan, Surmodics filings are updated as they are posted to EDGAR, and AI-powered summaries highlight the main points of lengthy documents. Users can quickly see what each filing covers, from financial condition and segment performance to cybersecurity events, merger completion steps, delisting notices, and changes in control. This makes it easier to understand how regulatory disclosures reflect Surmodics’ transition from a publicly traded issuer on Nasdaq to a privately held subsidiary of an affiliate of GTCR.
Surmodics Inc. (SRDX)$43.00 per share in cash, subject to tax withholding. All restricted stock units held by the insider vested immediately before the effective time and are also entitled to the same cash consideration. Following the merger, the insider reported owning 0 shares of common stock.
The filing also shows that multiple employee stock options with exercise prices ranging from $33.64 to $56.63 per share were cancelled on 11/19/2025 and converted into cash rights equal to the in-the-money value, again subject to tax withholding.
Surmodics Inc. (SRDX)$43.00 per share in cash, without interest and subject to tax withholding. For President & CEO and director Gary R. Maharaj, the filing shows that his remaining 192,056 shares of common stock were disposed of in connection with the merger, leaving him with no beneficial ownership of Surmodics common stock.
The filing also details that multiple employee stock options held by Maharaj, covering tens of thousands of shares each at exercise prices between $33.64 and $56.63, were cancelled and converted into cash. Each option is being settled for cash equal to the number of shares subject to the option multiplied by the excess of the $43.00 merger consideration over the option’s exercise price, subject to tax withholdings.
Surmodics, Inc. (SRDX) completed its previously announced merger with BCE Parent, LLC on November 19, 2025, with Surmodics becoming a wholly owned subsidiary of Parent. Each outstanding share of Surmodics common stock (with certain excluded shares) was converted into the right to receive $43.00 in cash per share, without interest. All outstanding restricted stock units, deferred stock units, restricted shares, and in-the-money stock options were cancelled in exchange for cash based on the same merger price.
In connection with closing, Surmodics repaid in full all obligations under its October 2022 Credit Agreement and terminated a related interest rate swap covering $25.0 million of term loans. The company notified Nasdaq, requested a trading halt, and is being delisted via Form 25, followed by a planned Form 15 to terminate registration and suspend reporting duties. A change in control occurred, the prior board and executive team resigned, and new directors and officers designated by the buyer were installed. The company’s articles and bylaws were also amended and restated at the effective time.
Surmodics (SRDX) reported a key legal development related to its pending acquisition by an affiliate of GTCR LLC. The U.S. District Court for the Northern District of Illinois denied a request by the FTC and certain state regulators for a preliminary injunction that would have prevented the parties from closing the merger.
The company furnished a press release as Exhibit 99.1. This ruling removes a major procedural barrier to closing, though completion of the merger still depends on remaining conditions described elsewhere by the company. The disclosure includes standard forward‑looking statement cautions.
Surmodics (SRDX) Q3 FY25 (period ended 30 Jun 2025) shows mixed performance. Total revenue slipped 3% YoY to $29.6 million as Medical Device sales softened 11% while In Vitro Diagnostics rose 6%. Operating loss was roughly flat at $5.2 million; net loss narrowed to $5.3 million (-$0.37 per share) from $7.6 million. For the nine-month period, revenue fell 6% to $87.6 million and net loss widened to $14.2 million.
Cash & liquidity: Cash and equivalents dropped to $26.3 million (vs $36.1 million at FY-end) after negative operating cash flow of $5.5 million. Long-term debt remains $29.7 million, giving net cash of -$3.4 million. Equity totals $111.3 million against total liabilities of $58.5 million.
Operational highlights: Commercial shipments of the SurVeil drug-coated balloon to Abbott continued; Pounce LP and XL thrombectomy systems and Sublime microcatheters completed limited evaluations and moved to full launch. A June cyber incident generated $1.9 million in costs, of which $1.7 million is expected to be recovered via insurance.
Strategic events: Shareholders approved the $43-per-share cash merger with BCE Parent (GTCR) on 13 Aug 2024, but the FTC filed suit on 6 Mar 2025 to block the deal. Surmodics has incurred $10.1 million of merger-related expenses YTD. Closing is subject to litigation outcome and other customary conditions.
On 8 Aug 2025 Surmodics, Inc. (SRDX) filed a Form 8-K to furnish a press release announcing its financial results for the quarter ended 30 Jun 2025. The press release is attached as Exhibit 99.1, but the filing itself contains no revenue, EPS, balance-sheet or guidance figures. The disclosure falls under Item 2.02 (Results of Operations and Financial Condition) and is expressly marked as “furnished,” not “filed,” which limits Section 18 Exchange Act liability. Aside from the exhibit list and standard representations, the document offers no additional financial data or strategic commentary.
Trium Capital LLP, a United Kingdom-based investment adviser, filed a Schedule 13G on 15 July 2025 reporting ownership of 716,783 shares of Surmodics, Inc. (SRDX), equal to 5.01 % of the company’s outstanding common stock. Trium has sole voting and dispositive power over the entire position and no shared authority with other parties. Because the filing is a Schedule 13G—rather than an activist 13D—the stake is declared to be held in the ordinary course of business, with no intent to influence control of Surmodics.
The disclosure moves Trium across the 5 % reporting threshold, adding another institutional holder to Surmodics’ register. While the passive nature of the investment means limited governance impact, heightened institutional ownership can improve liquidity, expand research coverage, and serve as a soft vote of confidence in Surmodics’ outlook. There is, however, no information on purchase price, timing of accumulation, or future trading plans, so market impact should be viewed as modest and primarily informational.